8-K/A: Medtronic Amends 8-K Filing to Detail Interim CFO's Compensation
Executive Compensation Update
Medtronic has updated its previous 8-K filing to include details of the compensation package for its interim Chief Financial Officer, Gary Corona.
Summary
- Medtronic has filed an amendment to its original 8-K report to disclose the compensation arrangements for interim CFO, Gary Corona.
- The original report, filed on June 26, 2024, announced Mr. Corona's appointment effective August 3, 2024.
- The Compensation Committee approved modifications to Mr. Corona's compensation on August 15, 2024.
- Mr. Corona will receive a biweekly cash stipend of $12,500, effective August 3, 2024.
- He will also receive an equity grant of 8,966 time-based restricted stock units (RSUs).
- The RSUs will vest over two years, with 50% vesting annually on the first and second anniversaries of the grant date.
- Mr. Corona's annual base salary remains at $500,000, with a target bonus of 70% of his base salary.
- He also received a long-term incentive grant of $1 million on July 29, 2024.
Sentiment
Score: 7
Explanation: The document is a routine update on executive compensation, which is generally neutral. The details are clear and transparent, which is positive.
Positives
- The compensation package for the interim CFO is clearly defined and includes both cash and equity components.
- The vesting schedule for the RSUs provides a long-term incentive for the interim CFO.
- The company has maintained the annual base salary, target bonus and long-term incentive grant for the interim CFO.
Industry Context
This announcement is typical for publicly traded companies when there are changes in key executive positions, ensuring transparency regarding compensation arrangements.
Comparison to Industry Standards
- The compensation package for Medtronic's interim CFO appears to be in line with industry standards for similar roles at large, publicly traded companies.
- Companies like Johnson & Johnson and Abbott, which are also in the medical device sector, typically offer similar combinations of base salary, bonuses, and equity grants to their executive leadership.
- The vesting schedule of the RSUs is a common practice to align the executive's interests with the long-term performance of the company.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Interim Chief Financial Officer | NA | Gary Corona | 2024-08-03 | Interim appointment |
Stakeholder Impact
- Shareholders are provided with transparency regarding executive compensation.
- Employees may view the compensation package as a sign of the company's commitment to attracting and retaining talent.
Key Dates
| Date | Description |
|---|---|
| 2024-06-21 | Date of earliest event reported in the original 8-K filing. |
| 2024-06-26 | Date of the original 8-K filing announcing Gary Corona's appointment as interim CFO. |
| 2024-07-29 | Date of the long-term incentive grant of $1 million to Gary Corona. |
| 2024-08-03 | Effective date of Gary Corona's appointment as interim CFO and the start date of his biweekly cash stipend. |
| 2024-08-15 | Date the Compensation Committee approved modifications to Gary Corona's compensation. |
| 2024-08-16 | Date of the amended 8-K/A filing. |
Keywords
compensation, interim CFO, restricted stock units, executive compensation, Medtronic, financial officer, 8-K filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.